Drug Overview
Perjeta is a humanized MAb that binds to subdomain II of the extracellular part of the HER2 protein.
Binding blocks ligand-dependent heterodimerization of HER2 with other HER family members,
including epidermal growth factor receptor, HER3, and HER4 (Perjeta prescribing information, 2015).
Perjeta inhibits ligand-initiated intracellular signaling through the mitogen-activated protein kinase
pathway and the phosphoinositide 3-kinase pathway. Preclinical tumor mouse xenograft models with
HER2-positive cells have demonstrated Perjeta’s antitumor activity in gastric cancer. In particular, the
combination of Perjeta plus Herceptin was shown to have enhanced antitumor efficacy compared
with single-agent therapy with either drug (Jorgenson, 2014).
Analyst Outlook
Perjeta (pertuzumab; Roche/Chugai) is a humanized monoclonal antibody (MAb) under development
for the treatment of metastatic gastric cancer expressing human epidermal growth factor receptor 2
(HER2). Perjeta has a distinct but complementary mechanism of action to Herceptin (trastuzumab;
Roche/Chugai). Preclinical models and early-phase clinical trials have demonstrated a potential
synergistic antitumor effect. Perjeta represents an important opportunity for Roche and Chugai to
maintain their dominance of the HER2-positive gastric cancer market, as looming patent expiries
threaten to erode branded sales of Herceptin and new HER2-targeted therapies attempt to penetrate
the market. However, the cost of treatment with Perjeta plus Herceptin and chemotherapy is expected
to be high. Phase III trials of Perjeta will have to demonstrate especially significant improvements in
patient outcomes in order to win favor in cost-conservative markets.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Perjeta : Gastric cancer
13 Perjeta : Ovarian cancer
21 Perjeta : Breast cancer: HER2-positive
LIST OF FIGURES
7 Figure 1: Perjeta for gastric cancer – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for Perjeta in gastric cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary for Perjeta in gastric cancer
17 Figure 4: Perjeta for ovarian cancer – SWOT analysis
18 Figure 5: Datamonitor Healthcare’s drug assessment of Perjeta for ovarian cancer
18 Figure 6: Datamonitor Healthcare’s drug assessment of Perjeta for ovarian cancer
25 Figure 7: Perjeta – SWOT analysis in HER2-positive breast cancer
26 Figure 8: Datamonitor Healthcare’s drug assessment summary of Perjeta for HER2-positive
breast cancer
27 Figure 9: Datamonitor Healthcare drug assessment summary of Perjeta for HER2-positive
breast cancer
LIST OF TABLES
4 Table 1: Perjeta drug profile
5 Table 2: Perjeta late-phase trial in gastric cancer
6 Table 3: Perjeta early-phase data in gastric cancer
13 Table 4: Perjeta drug profile
15 Table 5: Perjeta Phase III data in ovarian cancer
15 Table 6: Phase II data for Perjeta in ovarian cancer
21 Table 7: Perjeta (pertuzumab; Genentech/Roche/Chugai) – drug profile
23 Table 8: Overview of pivotal trial data for Perjeta in HER2-positive breast cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!